









Markets
/
Stocks
/
nasdaq-cers
/

Cerus Corp

CERS

1.745USD

-0.085-4.64%

Close 03/30, 16:00（ET）Quotes delayed by 15 min

94.95MMarket Cap

LossP/E TTM



Cerus Corp

1.745

-0.085-4.64%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Cerus Corp

Currency: USD Updated: 2026-03-27

Key Insights

Cerus Corp's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 90 out of 208 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 5.00.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Cerus Corp's Score

Industry at a Glance

Industry Ranking

90 / 208

Overall Ranking

220 / 4542

Industry

Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Cerus Corp Highlights

StrengthsRisks

Cerus Corporation is a biomedical products company. The Company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 25.16% year-on-year.

Undervalued

The company’s latest PE is -21.71, at a low 3-year percentile range.

Held by Invesco

Star Investor Invesco holds 251.52K shares of this stock.

Analyst Rating

Based on 3 analysts

Buy

Current Rating

5.000

Target Price

+173.22%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-27

The current financial score of Cerus Corp is 6.12, ranking 168 out of 208 in the Healthcare Equipment & Supplies industry. Its financial status is weak, and its operating efficiency is average. Its latest quarterly revenue reached 64.58M, representing a year-over-year increase of 13.79%, while its net profit experienced a year-over-year increase of 13.37%.

Score

Industry at a Glance

Previous score

6.12

Change



Financials

5.27

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

4.06

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

7.37

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.78

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.14

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Cerus Corp's Company Valuation

Currency: USD Updated: 2026-03-27

The current valuation score of Cerus Corp is 7.27, ranking 99 out of 208 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -21.71, which is -79.28% below the recent high of -4.50 and -49.95% above the recent low of -32.55.

Score

Industry at a Glance

Previous score

7.27

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 90/208

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-27

The current earnings forecast score of Cerus Corp is 7.33, ranking 134 out of 208 in the Healthcare Equipment & Supplies industry. The average price target is 5.00, with a high of 5.00 and a low of 4.00.

Score

Industry at a Glance

Previous score

7.33

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 3 analysts

Buy

Current Rating

5.000

Target Price

+180.90%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

115

Total

Median

Average

Company name

Ratings

Analysts

Cerus Corp

CERS

Medtronic PLC

MDT

Stryker Corp

SYK

Zimmer Biomet Holdings Inc

ZBH

Abbott Laboratories

ABT

Dexcom Inc

DXCM

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-27

The current price momentum score of Cerus Corp is 6.50, ranking 119 out of 208 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 2.43 and the support level at 1.37, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.60

Change

-0.1

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(5)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

0.021

Neutral

RSI(14)

39.834

Neutral

STOCH(KDJ)(9,3,3)

48.107

Neutral

ATR(14)

0.119

Low Volatility

CCI(14)

15.138

Neutral

Williams %R

50.000

Neutral

TRIX(12,20)

-1.109

Sell

StochRSI(14)

36.619

Sell

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

1.808

Sell

MA10

1.792

Sell

MA20

1.883

Sell

MA50

2.190

Sell

MA100

2.045

Sell

MA200

1.722

Buy

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of Cerus Corp is 7.00, ranking 81 out of 208 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 74.92%, representing a quarter-over-quarter decrease of 1.95%. The largest institutional shareholder is Catherine Wood, holding a total of 18.20M shares, representing 9.47% of shares outstanding, with 12.35% decrease in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

ARK Investment Management LLC

Star Investors

18.85M

-1.86%

BlackRock Institutional Trust Company, N.A.

15.58M

+0.98%

The Vanguard Group, Inc.

Star Investors

10.78M

+0.58%

Baker Bros. Advisors LP

10.01M

-22.32%

Wasatch Global Investors Inc

Star Investors

5.54M

-35.09%

BlackRock Financial Management, Inc.

4.26M

+2.41%

Amova Asset Management Co., Ltd.

5.69M

-6.34%

Silvercrest Asset Management Group LLC

4.12M

+18.29%

Geode Capital Management, L.L.C.

4.52M

+3.99%

Risk Assessment

Currency: USD Updated: 2026-03-27

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Cerus Corp is 3.99, ranking 115 out of 208 in the Healthcare Equipment & Supplies industry. The company's beta value is 1.62. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.